Major Depressive Disorder Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight

DelveInsight's 'Major Depressive Disorder Market Insights, Epidemiology, and Market Forecast - 2034' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of major depressive disorder in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Key Takeaways from the Major Depressive Disorder Market Research Report

* The increase in a number of Major Depressive Disorder cases and the launch of new therapies are likely to contribute to the market growth during the forecast period (2024-2034).
* As per DelveInsight analysis, the total diagnosed prevalent cases of MDD in the 7MM were found to be approximately 43 million cases in 2023, which is expected to increase during the study period (2020 2034).
* According to estimates based on DelveInsight's analysis, the US accounted for the highest i.e. nearly 51% of the total diagnosed prevalent cases of MDD in the 7MM in the year 2023. The cases are expected to increase further by 2034.
* According to DelveInsight analysts, gender-specific diagnosed prevalent cases of Major Depressive Disorder in the UK in 2023 were nearly 1.5 million for males and 2.5 million for females. These cases are expected to change during the forecast period.
* The leading Major Depressive Disorder Companies working in the market include Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Sirstei Pharmaceuticals, Alto Neuroscience, Chase Therapeutics, Neumora Therapeutics, BlackThorn Therapeutics, Otsuka Pharmaceutical Co., Fabre-Kramer Pharmaceuticals, Novartis, and others.
* Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include SEP-363856, Psilocybin, CTC-501, CYB003, NMRA 335140, PDC-1421 Capsule, SAGE-217, XEN1101, NBI-1065845, ANC-501, REL-1017, lumateperone, ALTO-300, TNX-601 ER, Aticaprant, BI 1569912, and others.
* April 2024:- Sirtsei Pharmaceuticals, Inc.- A Multi-center, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder. This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
* April 2024:- Neumora Therapeutics Inc.- A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder. This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo).

Discover which therapies are expected to grab the Major Depressive Disorder Market Share @ Major Depressive Disorder Market Outlook [https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Major Depressive Disorder Overview

Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders. It has been projected by the World Health Organization to be the leading cause of disease burden in high-income countries by 2034. Major depressive disorder is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.

Major Depressive Disorder Epidemiology Segmentation in the 7MM

* Major Depressive Disorder Gender-specific Diagnosed Prevalent Cases
* Total Major Depressive Disorder Diagnosed Prevalent Cases
* Major Depressive Disorder Severity-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving Major Depressive Disorder Epidemiology trends @ Major Depressive Disorder Epidemiological Insights [https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Major Depressive Disorder Market Insights

Major Depressive Disorder can be managed with various treatment modalities, including pharmacological, psychotherapeutic, interventional, and lifestyle modification. The initial treatment of MDD includes medications or/and psychotherapy. Combination treatment, including both medications and psychotherapy, is more effective than either of these treatments alone. Electroconvulsive therapy is found to be more efficacious than any other form of treatment for severe major depression. In recent years, psychotherapy has been shown to have effects on depression including attenuating depressive symptoms and improving quality of life.

Major Depressive Disorder Treatment Market Landscape

The Major Depressive Disorder market consists of various unmet needs which treatment to complete remission, treating cognitive impairment in depression, and novel and effective treatment strategies. In order to counter the market's current unmet needs and provide better treatment options for MDD, various research studies have focused on developing novel treatments for MDD, and several small molecules with novel mechanisms of action have been proposed. With the continuous efforts in research and development, drug such as Itruvone (PH10) (VistaGen Therapeutics), Zuranolone (SAGE Therapeutics/Biogen), LY03005 (Luye Pharma), and others are being developed for Major Depressive Disorder.

Major Depressive Disorder Emerging Therapies

* Zuranolone (SAGE Therapeutics/Biogen)
* LY03005 (Luye Pharma)
* Seltorexant (Janssen Pharmaceutical/Minerva Neurosciences)
* Itruvone (PH10) (VistaGen Therapeutics)

To know more about Major Depressive Disorder treatment guidelines, visit @ Major Depressive Disorder Treatment Market Landscape [https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Major Depressive Disorder Market Dynamics

The Major Depressive Disorder market dynamics are anticipated to change in the coming years owing to the improvement in the research and development undertaking. Several drugs targeting MDD are expected to enter the market including Zuranolone (SAGE Therapeutics/Biogen), LY03005 (Luye Pharma), REL-1017 (Relmada Therapeutics), seltorexant (Minerva Neurosciences/Janssen Pharmaceutical), ABV-1504 (BioLite/ABVC BioPharma), and other.

Major Depressive Disorder Drugs Uptake

* Zuranolone being developed by SAGE Therapeutics and Biogen is a novel, highly potent, and selective, next-generation, an oral, positive allosteric modulator optimized for selectivity to synaptic and extrasynaptic GABAA receptors. The binding sites for NASs are distinct from the recognition sites for GABA, benzodiazepines, and barbiturates. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS) and contributes significantly to regulating CNS function. SAGE-217 is currently being developed for MDD and is in phase III of clinical development. It is being evaluated in the LANDSCAPE and NEST clinical trial programs. The two development programs include multiple studies examining the use of zuranolone in several thousand people with a variety of dosing, clinical endpoints, and treatment paradigms.
* LY03005 being developed by Luye Pharma is one of Luye Pharma's key products in the CNS therapeutic area. It is the Group's exclusive ansofaxine hydrochloride, a serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI) in extended-release tablet form being developed for the treatment of MDD with the aim of achieving better efficacy and fewer side effects as compared to traditional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Ansofaxine is a triple reuptake inhibitor that potently blocks dopamine reuptake in addition to serotonin and norepinephrine transporters. It is a prodrug of desvenlafaxine (dual reuptake inhibitor of serotonin and norepinephrine) and has demonstrated better efficacy in clinical studies.
* Seltorexant being developed by Minerva Neurosciences and Janssen Pharmaceutical is a selective orexin-2 receptor antagonist as adjunctive therapy for MDD and for the treatment of insomnia disorder. Seltorexant is the most advanced specific ORX2 molecule in clinical development, with antagonistic activity when binding to its receptor. Seltorexant is currently being developed for two indications, insomnia without associated psychiatric disorders and MDD in patients who have an inadequate response to SSRIs and SNRIs. It is currently being evaluated in Phase III trials.

Learn more about the FDA-approved drugs for Major Depressive Disorder @ Drugs for Major Depressive Disorder Treatment [https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Major Depressive Disorder Market Report

* Coverage- 7MM
* Major Depressive Disorder Companies- Takeda Pharmaceuticals, Forest Laboratories, Otsuka Pharmaceuticals, Janssen Research & Development, Axsome Therapeutics, AbbVie, SAGE Therapeutics, Minerva Neurosciences, Luye Pharma, Relmada Therapeutics, BioLite Inc., VistaGen Therapeutics, Praxis Precision Medicines, Intra-Cellular Therapies, Neurocrine Biosciences, Arrivo Bioventures, Sirstei Pharmaceuticals, Alto Neuroscience, Chase Therapeutics, Neumora Therapeutics, BlackThorn Therapeutics, Otsuka Pharmaceutical Co., Fabre-Kramer Pharmaceuticals, Novartis, and others.
* Major Depressive Disorder Therapies- SEP-363856, Psilocybin, CTC-501, CYB003, NMRA 335140, PDC-1421 Capsule, SAGE-217, XEN1101, NBI-1065845, ANC-501, REL-1017, Lumateperone, ALTO-300, TNX-601 ER, Aticaprant, BI 1569912, and others.
* Major Depressive Disorder Market Dynamics: Major Depressive Disorder Market Drivers and Barriers
* Major Depressive Disorder Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Major Depressive Disorder Drugs in development @ Major Depressive Disorder Clinical Trials Assessment [https://www.delveinsight.com/sample-request/major-depressive-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Major Depressive Disorder Market Overview at a Glance

4. Executive Summary of Major Depressive Disorder

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Treatment and Management

8. Organizations contributing towards MDD

9. Patient Journey

10. Case Report

11. Marketed Therapies

12. Emerging Therapies

13. Other Assets

14. Discontinued Therapies

15. Major Depressive Disorder (MDD): 7 Major Market Analysis

16. SWOT Analysis

17. Unmet Needs

18. Market Access

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=major-depressive-disorder-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.